Scilex Presents ZTlido Data on Superior Adhesion over Lidocaine Patch Formulation

Scilex Pharmaceuticals Inc. (Scilex), a subsidiary of Sorrento Therapeutics, Inc. announced data showing ZTlido (lidocaine topical system) 1.8% (ZTlido) demonstrated a statistically significant improved adhesion profile compared to Lidoderm (lidocaine patch 5%) (Lidoderm) and Versatis (Medicated Plaster 5%) (Versatis)1. In a separate study, ZTlido was found to be bioequivalent to Lidoderm2. The presentation of results at PAINWeek 2018 in Las Vegas, September 4-8, followed U.S. Food and Drug Administration (FDA) approval in February for the relief of pain associated with post-herpetic neuralgia (PHN). ZTLIDO will be commercially available in October.

“Skin adhesion is important for the effectiveness of topical patches and systems, and these findings further establish ZTlido as a promising new treatment option for PHN,” said Jeff Gudin, M.D., Director, Pain Management and Palliative Care, Englewood Hospital and Medical Center. “We also found that while lidocaine topical patches and systems are a recommended non-opioid first-line therapy, they remain underutilized in clinical practice.”

ZTlido is a new topical product that uses an advanced adhesion technology providing more efficient lidocaine delivery than Lidoderm over a full 12 hours. PHN, also referred to as post-shingles pain, is a frequent complication of shingles, a condition caused by the herpes zoster (HZ) virus4.

“The results of these studies reinforce the value of ZTlido as a first-line, non-opioid therapy for this difficult-to-treat condition,” said William Pedranti, President of Operations for Scilex. “We are thrilled with the data and will continue to explore additional indications as well as using the underlying technology platform for other active pharmaceutical ingredients.”